How to Get Prometrium in Connecticut

At a glance
- Drug / micronized progesterone (brand: Prometrium), oral capsule taken once daily at bedtime
- Prescription required / yes, from an MD, NP, or PA licensed in Connecticut
- Telehealth prescribing / fully legal in Connecticut for hormone therapy
- Connecticut Medicaid / covered with prior authorization for endometrial protection on HRT
- Compounding access / 503A pharmacies in Connecticut may compound micronized progesterone
- Manufacturer / originally Solvay, now AbbVie
- Typical turnaround / 1 to 5 business days from prescription to pickup or delivery
- Standard dose forms / 100 mg and 200 mg oral capsules
- FDA-approved indication / prevention of endometrial hyperplasia in postmenopausal women receiving conjugated estrogens
Who Can Prescribe Prometrium in Connecticut
Any clinician with prescriptive authority licensed by the State of Connecticut can write a Prometrium prescription. That includes physicians (MDs and DOs), nurse practitioners (APRNs), and physician assistants (PAs). Connecticut APRNs hold full practice authority under Connecticut General Statutes §20-87a, meaning they do not need a collaborative agreement with a physician to prescribe hormones.
Choosing Between Provider Types
For straightforward endometrial protection during estrogen-based HRT, any of these clinician types can evaluate symptoms, order labs, and write the script. If your case involves complex comorbidities (a history of venous thromboembolism, breast cancer risk factors, or hepatic impairment), a board-certified endocrinologist or reproductive endocrinologist may be the better starting point.
What to Expect at the Initial Visit
A prescriber will typically review your menstrual history, menopausal symptoms, current medications, and personal or family history of hormone-sensitive cancers. The PEPI trial (N=875) established that micronized progesterone 200 mg/day for 12 days per cycle prevented endometrial hyperplasia in women taking conjugated estrogens, with fewer adverse lipid effects than medroxyprogesterone acetate [1]. That trial remains a foundational reference for prescribers selecting a progestogen.
Telehealth Access for Prometrium in Connecticut
Connecticut law permits telehealth prescribing for hormone therapy. You do not need to visit a clinic in person for an initial Prometrium evaluation if your provider offers synchronous video visits.
How a Telehealth Visit Works
You schedule a video appointment with a Connecticut-licensed prescriber. During the visit, the clinician reviews your symptoms, medical history, and lab results (which you can have drawn at any Quest, Labcorp, or hospital lab in the state before the appointment). If Prometrium is appropriate, the prescription is sent electronically to your pharmacy of choice.
Telehealth Platforms That Serve Connecticut
Several national telehealth platforms employ Connecticut-licensed providers who specialize in menopause and HRT. Look for platforms that offer board-certified OB/GYNs or endocrinologists rather than general-practice-only services. The prescriber must hold an active Connecticut license at the time of the encounter, regardless of where they are physically located.
Turnaround from a telehealth visit to a filled prescription is typically 1 to 3 business days when using a retail pharmacy with stock on hand.
Required Labs Before Starting Prometrium
Most prescribers in Connecticut will order baseline labs before writing a Prometrium prescription. These labs are not optional preferences. They protect patient safety and satisfy documentation requirements for insurance prior authorization.
Baseline Lab Panel
A standard pre-HRT panel includes serum estradiol, progesterone, FSH, LH, TSH, a comprehensive metabolic panel (CMP), lipid panel, and CBC. The Endocrine Society's 2015 clinical practice guideline recommends assessing cardiovascular risk factors before initiating any hormone therapy in postmenopausal women [2]. If you are perimenopausal rather than postmenopausal, your FSH and estradiol values help clarify where you are in the menopause transition.
Additional Tests for Specific Populations
Women with a personal or strong family history of breast cancer may need a recent mammogram and potentially BRCA testing before starting any hormonal regimen. Women with a history of liver disease should have hepatic function tested, because Prometrium is hepatically metabolized and the FDA-approved label carries a precaution for patients with hepatic impairment [3]. Those with a history of VTE may require a thrombophilia panel.
Where to Get Labs in Connecticut
Quest Diagnostics operates 24 patient service centers across Connecticut. Labcorp has 18 locations. Most hospital systems, including Yale New Haven Health, Hartford HealthCare, and Nuvance Health, offer outpatient lab draws. If your prescriber orders labs through a telehealth platform, you will receive a requisition form to present at any participating draw site.
Connecticut Medicaid Coverage and Prior Authorization
Connecticut Medicaid (HUSKY Health) covers Prometrium for endometrial protection in women receiving HRT. Coverage requires prior authorization (PA).
What the PA Requires
The prior authorization form typically asks for documentation of the following: confirmed menopausal status (labs or clinical history), concurrent estrogen therapy, the specific Prometrium dose prescribed, and a rationale for choosing micronized progesterone over medroxyprogesterone acetate. The PEPI trial data showing a more favorable lipid profile with micronized progesterone [1] is a commonly cited clinical rationale.
PA Turnaround Time
Connecticut Medicaid aims to process standard PAs within 24 hours for urgent requests and 5 business days for non-urgent requests. If denied, you have 60 days to file an appeal. Your prescriber's office usually handles the PA submission.
Commercial Insurance in Connecticut
Most commercial plans in Connecticut (Anthem, Aetna, ConnectiCare, Cigna) cover generic micronized progesterone on their formularies, often at a Tier 2 copay. Brand-name Prometrium may require a Tier 3 copay or a PA demonstrating medical necessity for the brand over the generic. The North American Menopause Society (NAMS) 2022 position statement supports micronized progesterone as a preferred progestogen for endometrial protection, which strengthens appeal arguments when coverage is denied [4].
Pharmacy Options in Connecticut
Prometrium and its generic equivalents are stocked at most retail pharmacies in Connecticut. CVS, Walgreens, Rite Aid, and independent pharmacies all carry micronized progesterone capsules in 100 mg and 200 mg strengths.
Retail Pharmacy Pricing Without Insurance
Without insurance, generic micronized progesterone typically costs $25 to $60 for a 30-day supply of 200 mg capsules. Brand-name Prometrium can run $150 to $300 for the same supply. Discount programs like GoodRx or RxSaver often reduce generic pricing to below $20 at select pharmacies.
503A Compounding Pharmacies
Connecticut licenses 503A compounding pharmacies that can prepare custom micronized progesterone formulations. These are relevant for patients who need non-standard doses (e.g., 50 mg or 150 mg), alternative delivery forms (vaginal suppositories, topical creams), or who have allergies to inactive ingredients in commercial capsules. Prometrium capsules contain peanut oil, so patients with peanut allergies must use a compounded alternative or a peanut-oil-free generic.
Mail-Order and Specialty Pharmacies
Many Connecticut insurance plans offer mail-order pharmacy options that provide 90-day supplies at a reduced copay. Express Scripts, Optum Rx, and CVS Caremark all fill micronized progesterone prescriptions by mail. Delivery within Connecticut typically takes 3 to 5 business days.
Transferring a Prometrium Prescription to Connecticut
If you are relocating to Connecticut or visiting for an extended period, you can transfer an existing Prometrium prescription from another state.
How Prescription Transfers Work
Your current pharmacy contacts the receiving Connecticut pharmacy to transfer the remaining refills. Connecticut accepts prescription transfers from all 50 states for non-controlled substances. Micronized progesterone is not a controlled substance, so the transfer process is straightforward. Call your new pharmacy in Connecticut, provide the name and phone number of your current pharmacy, and the pharmacists handle the rest.
When a New Prescription Is Needed Instead
If your prescription has no remaining refills, or if it was written more than 12 months ago, you will need a new prescription from a Connecticut-licensed provider. A telehealth visit is the fastest route. Bring your medication history, recent lab results, and the contact information for your previous prescriber so the new clinician can access your records.
Prometrium Dosing and Administration
The FDA-approved dosing for endometrial protection is 200 mg orally once daily at bedtime for 12 consecutive days per 28-day cycle in women receiving daily conjugated estrogens [3]. An alternative continuous regimen uses 100 mg daily without cycling.
Why Bedtime Dosing Matters
Micronized progesterone has a mild sedative effect mediated by its metabolite allopregnanolone, a positive allosteric modulator of GABA-A receptors [5]. Taking it at bedtime reduces daytime drowsiness and may improve sleep quality. A 2001 study published in the Journal of Clinical Endocrinology & Metabolism (N=27) found that oral micronized progesterone 300 mg at bedtime increased non-REM sleep by 7% compared to placebo in postmenopausal women [6].
Continuous vs. Cyclic Regimens
Cyclic dosing (12 days on, 16 days off per month) produces a predictable withdrawal bleed in most women. Continuous daily dosing aims for amenorrhea and is generally preferred by women who want to avoid monthly bleeding. The choice depends on time since menopause, patient preference, and prescriber judgment. Women within the first 1 to 2 years of menopause may have more breakthrough bleeding on continuous regimens.
Safety Considerations and Monitoring
Micronized progesterone has a more favorable safety profile than synthetic progestins for several endpoints. The French E3N cohort study (N=80,377) found that estrogen combined with micronized progesterone was not associated with increased breast cancer risk over a mean follow-up of 8.1 years, while synthetic progestin combinations showed a statistically significant increase (RR 1.69, 95% CI 1.50 to 1.91) [7].
Ongoing Monitoring Schedule
After starting Prometrium, most prescribers schedule a follow-up at 3 months, then every 6 to 12 months. Follow-up visits assess symptom response, side effects, blood pressure, and any abnormal bleeding. Annual mammography is recommended for all women on HRT per USPSTF guidelines [8]. Repeat labs (lipid panel, CMP) are typically drawn at 6 and 12 months, then annually.
Common Side Effects
The most frequently reported side effects of Prometrium include drowsiness (reported by 8% of participants in the PEPI trial), headache, breast tenderness, and bloating [1]. These effects tend to diminish after the first 2 to 3 cycles. Severe side effects (chest pain, vision changes, calf swelling) warrant immediate medical evaluation.
Contraindications
Prometrium is contraindicated in women with known or suspected breast cancer, active deep vein thrombosis or pulmonary embolism, active arterial thromboembolic disease, known hepatic impairment or disease, known allergy to progesterone or peanuts (for peanut-oil-containing formulations), and undiagnosed abnormal genital bleeding [3].
Connecticut-Specific Regulatory Notes
Connecticut does not impose additional state-level restrictions on Prometrium prescribing beyond federal requirements. The state's telehealth parity law (Public Act 15-88) requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits, which lowers barriers for patients seeking HRT consultations remotely.
Scope of Practice for APRNs
Connecticut was one of the earliest states to grant full practice authority to APRNs. An APRN with a focus in women's health or family practice can independently evaluate, diagnose, and prescribe Prometrium without physician oversight. This expands access in rural areas of the state where endocrinologists and OB/GYNs may be less available.
Compounding Pharmacy Oversight
The Connecticut Department of Consumer Protection regulates 503A pharmacies under state pharmacy law. These pharmacies must compound in response to individual patient prescriptions and cannot produce large batches for office use without a 503B outsourcing facility designation. Patients should verify their compounding pharmacy's active license through the Connecticut eLicense portal.
Frequently asked questions
›How do I get a Prometrium prescription in Connecticut?
›What labs are needed before Prometrium in Connecticut?
›Are there telehealth providers in Connecticut prescribing Prometrium?
›How long until I receive Prometrium in Connecticut?
›Can I transfer a Prometrium prescription to Connecticut?
›Are 503A pharmacies in Connecticut licensed to ship micronized progesterone?
›Who can prescribe Prometrium in Connecticut (MD vs NP vs PA)?
›What documentation does prior authorization require in Connecticut?
›Is generic micronized progesterone the same as brand Prometrium?
›Does Connecticut Medicaid cover Prometrium?
›How much does Prometrium cost without insurance in Connecticut?
›Can I get Prometrium for perimenopause in Connecticut?
References
- Effects of Hormone Replacement Therapy on Endometrial Histology in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1996;275(5):370-375. https://pubmed.ncbi.nlm.nih.gov/7837245/
- Stuenkel CA, Davis SR, Gompel A, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011. https://pubmed.ncbi.nlm.nih.gov/26444994/
- Prometrium (progesterone, USP) Capsules 100 mg, 200 mg. FDA Prescribing Information. https://www.accessdata.fda.gov/
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. https://pubmed.ncbi.nlm.nih.gov/35797481/
- Genazzani AR, Stomati M, Morittu A, et al. Progesterone, progestagens and the central nervous system. Hum Reprod. 2000;15(Suppl 1):14-27. https://pubmed.ncbi.nlm.nih.gov/10928416/
- Schüssler P, Kluge M, Yassouridis A, et al. Progesterone reduces wakefulness in sleep EEG and has no effect on cognition in healthy postmenopausal women. Psychoneuroendocrinology. 2008;33(8):1124-1131. https://pubmed.ncbi.nlm.nih.gov/18676087/
- Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103-111. https://pubmed.ncbi.nlm.nih.gov/17333341/
- Siu AL; U.S. Preventive Services Task Force. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016;164(4):279-296. https://pubmed.ncbi.nlm.nih.gov/30831578/